Announcements Trials
Browse Landscape

Phase

Phase 1 4Phase 3 3Phase 1/2 3Phase 2 2

Status

Completed 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1

Conditions

Small Cell Lung Carcinoma 1Recurrence 1Neoplasms 1

Interventions

Carboplatin 273Paclitaxel 267Gemcitabine 244Bevacizumab 226Cisplatin 218pembrolizumab 214Docetaxel 210Pemetrexed 162Capecitabine 148Fluorouracil 129Oxaliplatin 121Cyclophosphamide 121Nivolumab 112Dexamethasone 100Trastuzumab 89Leucovorin 87Cetuximab 85Rituximab 83Irinotecan 82Injections 81Erlotinib Hydrochloride 70Prednisone 68Doxorubicin 68Temozolomide 67atezolizumab 65Bortezomib 65Ipilimumab 64Fulvestrant 59Radiotherapy 54Drug Therapy 51

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × INDUSTRY × rovalpituzumab tesirine × Clear all
NCT02674568 2021-07-30

TRINITY

AbbVie

Phase 2 Completed
342 enrolled 18 charts
Thoracic

Recurrence, Small Cell Lung Carcinoma

NCT03543358 2021-01-05

A Long-Term Study of Rovalpituzumab Tesirine

AbbVie

Phase 2 Completed
3 enrolled 6 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡